An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo

Abstract

An oxaliplatin-based platinum(<sc>iv</sc>) drug which specifically binds to albumin after i.v. application led to several complete responses in tumor-bearing mice.